Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. Brain tumor research and treatment Nicholas, S., Mathios, D., Ruzevick, J., Jackson, C., Yang, I., Lim, M. 2013; 1 (1): 2–8

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain cancer. Even with aggressive combination therapy, the median life expectancy for patients with GBM remains approximately 14 months. In order to improve the outcomes of patients with GBM, the development of newer treatments is critical. The concept of using the immune system as a therapeutic option has been suggested for several decades; by harnessing the body's adaptive immune mechanisms, immunotherapy could provide a durable and targeted treatment against cancer. However, many cancers, including GBM, have developed mechanisms that protect tumor cells from being recognized and eliminated by the immune system. For new immunotherapeutic regimens to be successful, overcoming immunosuppression via immune checkpoint signaling should be taken into consideration.

View details for DOI 10.14791/btrt.2013.1.1.2

View details for PubMedID 24904882